INVIVYD, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
INVIVYD, INC. (IVVD) had Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of 0 shares as of 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber · last filed 2024-03-28
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 0.00 shares.
- 2023-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 31.77K shares.
- 2023-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 31.77K shares.
- 2023-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 93.48K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number |
|---|---|
| 2023-12-31 | 0.00 shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 31.77K shares 10-Q · filed 2023-11-09 |
| 2023-06-30 | 31.77K shares 10-Q · filed 2023-08-10 |
| 2023-03-31 | 93.48K shares 10-Q · filed 2023-05-11 |
| 2022-12-31 | 360.33K shares 10-K · filed 2024-03-28 |
| 2022-09-30 | 420.39K shares 10-Q · filed 2022-11-10 |
| 2022-06-30 | 480.44K shares 10-Q · filed 2022-08-15 |
| 2022-03-31 | 1.66M shares 10-Q · filed 2022-05-13 |
| 2021-12-31 | 3.08M shares 8-K · filed 2024-02-09 |
| 2021-09-30 | 3.86M shares 10-Q · filed 2021-11-15 |
| 2021-06-30 | 4.19M shares 10-Q · filed 2021-09-20 |
| 2020-12-31 | 5.59M shares 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |